BR112013017845A2 - agente antidiabético de abaixamento de lipídio - Google Patents
agente antidiabético de abaixamento de lipídioInfo
- Publication number
- BR112013017845A2 BR112013017845A2 BR112013017845A BR112013017845A BR112013017845A2 BR 112013017845 A2 BR112013017845 A2 BR 112013017845A2 BR 112013017845 A BR112013017845 A BR 112013017845A BR 112013017845 A BR112013017845 A BR 112013017845A BR 112013017845 A2 BR112013017845 A2 BR 112013017845A2
- Authority
- BR
- Brazil
- Prior art keywords
- antidiabetic agent
- lipid lowering
- composition
- lowering
- lipid
- Prior art date
Links
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
- C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161461113P | 2011-01-12 | 2011-01-12 | |
| US13/348,265 US20120178813A1 (en) | 2011-01-12 | 2012-01-11 | Lipid-lowering antidiabetic agent |
| PCT/US2012/021070 WO2012097144A1 (en) | 2011-01-12 | 2012-01-12 | Lipid-lowering antidiabetic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013017845A2 true BR112013017845A2 (pt) | 2019-09-24 |
Family
ID=46455756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013017845A BR112013017845A2 (pt) | 2011-01-12 | 2012-01-12 | agente antidiabético de abaixamento de lipídio |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20120178813A1 (enExample) |
| EP (1) | EP2663186A4 (enExample) |
| JP (1) | JP5911514B2 (enExample) |
| KR (1) | KR20140092228A (enExample) |
| CN (1) | CN103533833B (enExample) |
| AU (1) | AU2012205547B2 (enExample) |
| BR (1) | BR112013017845A2 (enExample) |
| CA (1) | CA2824192A1 (enExample) |
| EA (1) | EA201391028A1 (enExample) |
| IL (1) | IL227346A0 (enExample) |
| MX (1) | MX2013008131A (enExample) |
| WO (1) | WO2012097144A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| BR112015000368A2 (pt) * | 2012-07-10 | 2017-06-27 | Thetis Pharmaceuticals Llc | forma de tri-sais de metformina |
| WO2014080307A2 (en) * | 2012-11-21 | 2014-05-30 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| WO2014195810A2 (en) * | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| SG11201509782TA (en) * | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| WO2015022613A1 (en) * | 2013-08-11 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| WO2015171516A1 (en) * | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| BR112016029476A2 (pt) | 2014-06-18 | 2017-08-22 | Thetis Pharmaceuticals Llc | complexos de aminoácido mineral de agentes ativos |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| WO2016132186A1 (en) * | 2015-02-20 | 2016-08-25 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| US9371276B1 (en) * | 2015-03-21 | 2016-06-21 | Mohan Murali Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| JP6906047B2 (ja) | 2016-06-03 | 2021-07-21 | テティス・ファーマシューティカルズ・エルエルシー | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 |
| EP3648748A1 (en) | 2017-07-06 | 2020-05-13 | Evonik Operations GmbH | Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts |
| AU2018317802B2 (en) | 2017-08-15 | 2024-04-04 | Evonik Operations Gmbh | Tablets with high active ingredient content of omega-3 fatty acid amino acid salts |
| US11497722B2 (en) * | 2017-12-18 | 2022-11-15 | Soochow University | Use of metformin salt in the treatment of cerebral infarction |
| WO2021023857A1 (en) | 2019-08-08 | 2021-02-11 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
| CA3146612A1 (en) | 2019-08-08 | 2021-02-11 | Evonik Operations Gmbh | Down streaming process for the production of polyunsaturated fatty acid salts |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN115192625A (zh) * | 2022-06-30 | 2022-10-18 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| CA2400804C (en) | 2000-02-04 | 2009-09-01 | Takeda Chemical Industries, Ltd. | Stable emulsion compositions of cycloalkene derivatives |
| US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| US6667064B2 (en) | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| FR2818906B1 (fr) * | 2000-12-29 | 2004-04-02 | Dospharma | Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine |
| DE10102050A1 (de) | 2001-01-17 | 2002-07-18 | Basf Ag | Zubereitung zur Verbesserung der Nahrungsverwertung |
| WO2002079139A1 (de) | 2001-03-29 | 2002-10-10 | Basf Aktiengesellschaft | Konjugierte ungesättigte glyceridgemische und verfahren zur ihrer herstellung |
| AU2002335689B2 (en) | 2001-08-31 | 2008-08-07 | Rutgers, The State University Of New Jersey | Methods for treating disorders using plant extracts |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| WO2004004693A1 (en) * | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| MXPA05003346A (es) * | 2002-09-27 | 2005-11-23 | Martek Biosciences Corp | Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico. |
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| RU2356247C2 (ru) * | 2003-03-18 | 2009-05-27 | Новартис Аг | Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор |
| EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
| US20080045559A1 (en) | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| DE602004027936D1 (de) | 2003-10-29 | 2010-08-12 | Sonus Pharmaceutical Inc | Tocopherolmodifizierte therapeutische arzneimittelverbindung |
| US20050163849A1 (en) | 2003-10-31 | 2005-07-28 | Wong Patrick S. | Compositions and dosage forms for enhanced absorption of iron |
| AU2005205882A1 (en) | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist |
| WO2005118612A1 (en) | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
| US20100021555A1 (en) * | 2004-10-15 | 2010-01-28 | Karl Geiringer | Compositions containing high omega-3 and low saturated fatty acid levels |
| CN101094683A (zh) | 2004-10-29 | 2007-12-26 | J·坎贝尔－托夫特 | 从催吐萝芙木和酸橙中分离的抗糖尿病提取物及其使用方法 |
| CA2613875C (en) | 2005-07-04 | 2018-09-25 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| US7666898B2 (en) | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
| WO2007091070A1 (en) * | 2006-02-07 | 2007-08-16 | Universitetet I Oslo | Omega 3 |
| JP2009526747A (ja) | 2006-02-16 | 2009-07-23 | 武田薬品工業株式会社 | 環状アミン化合物および高血圧の予防・治療のための用途 |
| US20090047340A1 (en) | 2006-03-29 | 2009-02-19 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis |
| JP2009541220A (ja) | 2006-06-16 | 2009-11-26 | インディジーン ファーマシューティカルズ インコーポレイテッド | 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート |
| EP2094640A4 (en) | 2006-11-01 | 2015-05-20 | Pronova Biopharma Norge As | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR) |
| WO2008053340A1 (en) * | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
| WO2008058274A2 (en) * | 2006-11-09 | 2008-05-15 | Children's Medical Center Corporation | Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization |
| WO2008093984A1 (en) * | 2007-01-29 | 2008-08-07 | Hanall Pharmaceutical Company. Ltd | N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| TW200904433A (en) | 2007-04-27 | 2009-02-01 | Takeda Pharmaceutical | Substituted imidazole compound and use thereof |
| US20090227560A1 (en) | 2007-04-27 | 2009-09-10 | Takanobu Kuroita | Substituted imidazole compound and use thereof |
| US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
| JP5292404B2 (ja) * | 2007-09-21 | 2013-09-18 | ハンオル バイオファーマ カンパニー，リミテッド | Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物 |
| WO2009051112A1 (ja) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
| NZ589390A (en) | 2008-05-05 | 2011-11-25 | Oramed Ltd | Methods and compositions for oral administration of exenatide |
| PE20140858A1 (es) | 2008-06-19 | 2014-08-04 | Takeda Pharmaceutical | Derivados de piperidina como inhibidores de renina |
| NZ807894A (en) * | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US20110052678A1 (en) | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
-
2012
- 2012-01-11 US US13/348,265 patent/US20120178813A1/en not_active Abandoned
- 2012-01-12 EP EP12734013.1A patent/EP2663186A4/en not_active Withdrawn
- 2012-01-12 CN CN201280005222.1A patent/CN103533833B/zh not_active Expired - Fee Related
- 2012-01-12 JP JP2013549539A patent/JP5911514B2/ja not_active Expired - Fee Related
- 2012-01-12 KR KR20137018679A patent/KR20140092228A/ko not_active Withdrawn
- 2012-01-12 EA EA201391028A patent/EA201391028A1/ru unknown
- 2012-01-12 MX MX2013008131A patent/MX2013008131A/es not_active Application Discontinuation
- 2012-01-12 WO PCT/US2012/021070 patent/WO2012097144A1/en not_active Ceased
- 2012-01-12 CA CA2824192A patent/CA2824192A1/en not_active Abandoned
- 2012-01-12 BR BR112013017845A patent/BR112013017845A2/pt not_active IP Right Cessation
- 2012-01-12 AU AU2012205547A patent/AU2012205547B2/en not_active Ceased
-
2013
- 2013-06-21 US US13/923,829 patent/US8901107B2/en not_active Expired - Fee Related
- 2013-07-04 IL IL227346A patent/IL227346A0/en unknown
- 2013-12-20 US US14/136,843 patent/US9012507B2/en not_active Expired - Fee Related
-
2014
- 2014-10-27 US US14/524,721 patent/US9216951B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103533833A (zh) | 2014-01-22 |
| EP2663186A4 (en) | 2014-09-24 |
| JP2014512333A (ja) | 2014-05-22 |
| WO2012097144A1 (en) | 2012-07-19 |
| JP5911514B2 (ja) | 2016-04-27 |
| EP2663186A1 (en) | 2013-11-20 |
| CN103533833B (zh) | 2016-08-31 |
| CA2824192A1 (en) | 2012-07-19 |
| EA201391028A1 (ru) | 2013-12-30 |
| US20140107360A1 (en) | 2014-04-17 |
| US9012507B2 (en) | 2015-04-21 |
| US20130281535A1 (en) | 2013-10-24 |
| IL227346A0 (en) | 2013-09-30 |
| KR20140092228A (ko) | 2014-07-23 |
| MX2013008131A (es) | 2014-01-08 |
| AU2012205547B2 (en) | 2015-08-27 |
| AU2012205547A1 (en) | 2013-08-01 |
| US20120178813A1 (en) | 2012-07-12 |
| US8901107B2 (en) | 2014-12-02 |
| US20150051284A1 (en) | 2015-02-19 |
| US9216951B2 (en) | 2015-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013017845A2 (pt) | agente antidiabético de abaixamento de lipídio | |
| CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| CL2014000314A1 (es) | Compuestos derivados de ciclopropanamina, inhibidores de desmetilasa especifica de lisina 1 (lsd1); medicamento que los comprende; metodo para profilaxis o tratamiento; metodo para inhibir lsd1; y su uso en la profilaxis o tratamiento de esquizofrenia, enfermedad de alzheimer, enfermedad de parkinson o corea de huntington. | |
| BRPI0915536A2 (pt) | salicilatos acetilados de ácidos graxos e seus usos | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| ECSP12012097A (es) | Derivados de fumarato de ácido graso y sus usos | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112015009746A2 (pt) | Agente que aumenta atividade de glicocerebrosidase em mamíferos | |
| BR112013019257A2 (pt) | composição de androgênio para tratar uma condição oftálmica | |
| UY33766A (es) | COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2 | |
| CL2015000289A1 (es) | Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado. | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| GT201300313A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| BR112014014378A2 (pt) | composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico | |
| BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| NI201400042A (es) | 2 - tiopirimidinonas | |
| BR112013001301A2 (pt) | processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana | |
| BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
| BR112014027047A2 (pt) | nova formulação | |
| BR112013010367A2 (pt) | métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |